Lay’s recall increased to highest level, could cause ‘death’: FDA
The oversight could result in “death,” at least for those with a milk allergy or sensitivity, says the FDA. FDA initiated the ...
Axsome gets FDA approval for Symbravo for migraine
Axsome Therapeutics (NASDAQ:AXSM) has received FDA approval for its drug Symbravo for the acute treatment of migraine with or ...
The Return of Snake Oil
The Trump administration is poised to supercharge America’s appetite for supplements.
Do food warning labels actually work? Answering your questions.
Readers had a lot to say about my latest column on the Food and Drug Administration’s proposed front-of-package labels. Most ...
R Street Institute1hOpinion
Trump: Look at the Slow-Moving FDA
The Food and Drug Administration’s approval of low-risk tobacco pouches is welcome, but why did it delay for more than four ...
US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.
Walmart's Broccoli Recall Now Classified as Potentially Deadly, According to the FDA
In early January it was revealed that Walmart's washed and ready-to-eat 12 oz. Marketside Broccoli Florets were voluntarily ...
Chocolate Recall Now Classified As Potentially Deadly, According To The FDA
Per the FDA, the recalled Cal Yee’s (or Cal Yee Farm branded) products were packaged in clear plastic zippered pouches in ...
US FDA identifies cybersecurity risks in certain patient monitors
The U.S. Food and Drug Administration (FDA) said on Thursday it had identified three cybersecurity risks associated with ...
Chocolate recall upgraded to highest risk level, FDA announces
STATEN ISLAND, N.Y. — A December 2024 chocolate recall has been upgraded to highest risk level by the U.S. Food and Drug ...
WPLG4h
Certain Lay’s potato chips considered ‘high risk’ according to FDA recall
The U.S. Food & Drug Administration has recalled a popular brand of potato chips saying the product may be high risk for some ...
The American Journal of Managed Care5h
Oncology R&D Will Follow Divergent Paths, Experts Say at JPM Event
A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.